Pittsburgh, PA (PRWEB) September 27, 2011
Ortho-tag, a high-technology development and sales company based in Pittsburgh, PA, announces the appointment of Ken Laing as Chief Executive Officer. As CEO, Mr. Laing will lead strategic initiatives to market the company’s smart orthopedic implants transcutaneous near field communication chips (TNFC) and bio-sensor technologies.
Mr. Laing’s senior executive leadership experience includes organizational management of international high-tech companies, as well as the restructuring and running of a neurological hospital in his native Sydney, Australia. Mr. Laing brings a unique global vision that will play a key role in domestic as well as international business development, and the continued growth of Ortho-tag. In just a few short weeks after his appointment, Mr. Laing raised $1.6 million and is confident will be profitable by second fiscal quarter 2012.
“I am honored to have the opportunity to lead this innovative company with such incredible potential and to uniquely apply TNFC technology to the medical industry,” commented Laing. “Ortho-tag will provide cutting-edge technology advancements to the way surgeons monitor their patients, and will contribute to the future integration between smart implants and telemedicine.”
The surgical application of TNFC in the field of Orthopedics was conceived and patented by J. Lee Berger, MD and developed with Dr. Marlin Mickle, Professor and Director of the University of Pittsburgh RFID Center of Excellence.
According to Dr. Berger, “Smart identification and monitoring of total hip and total knee implants protects patients. Ortho-tag predicts this will result in fewer post-operative complications, reduction of over-all treatment cost and improved quality of healthcare.”
An “Orthotag” provides a post-operative, non-invasive solution to obtaining patient information regarding medical implants and post-operative diagnostics in the surrounding joint and tissue environment. TNFC chips and bio-sensors that are embedded into implants provide more reliable information and accountability regarding medical devices. This includes manufacturing information about the implant, surgical, and patient information. In addition, an orthotag will have the unique ability to monitor an implant’s biological environment in order to detect deep tissue infection and prevent the body from rejecting the implant.
Ortho-Tag is a high-technology development and sales company that is dedicated to improving surgical outcomes through its patented solutions that combine low cost and non-invasive TNFC and bio-sensor applications with implantable medical devices. For more information, visit http://www.ortho-tag.com
Editor’s Note: Total Joint Replacement (TJR) represents the largest single category of hospital care (Diagnosis Related Group) for Medicare beneficiaries. TJR is spreading rapidly to younger patients who seek better mobility and less chronic pain than earlier generations. The American Academy of Orthopedic Surgeons (AAOS) projects a 673 percent spike in total-knee replacements and a 174 percent increase in first-time total-hip replacements by 2030.